therapeutically effective complement inhibition at dosages below 0.003 g/kg.--

REMARKS

The above claims are being added to this application to further define applicants' invention. Both of these claims are dependent on Claim 1, which is one of the Group I claims that applicants elected for further prosecution in this application.

Claim 32 has a structure identical to pending Claim 6, which is a Group I claim. Claim 32 differs from Claim 6 in that it refers to an antibody concentration that yields a ratio equal to or less than 3 moles of antibody-antigen binding sites of the antibody to 1 mole of human C5, while Claim 6 refers to a ratio of 10. Support for Claim 32 can be found at, for example, page 45, lines 2-5, of applicants' specification.

Claim 33 has a structure similar, but not identical, to that of pending Claims 18 and 19, which are again Group I claims. This claim specifies that the antibody of Claim 1 provides therapeutically effective complement inhibition at dosages below 0.003 g/kg, whereas Claim 18 specifies that the antibody provides complete complement inhibition at dosages below 0.005 g/kg and Claim 19 specifies that the antibody provides therapeutic benefits at dosages below 0.0022 g/kg. Support for Claim 33 can be found at, for example, page 27, lines 24-26 and 35, of applicants' specification.

Incorporation of Claims 32 and 33 into Group I and the allowance of all of the claims of that group are respectfully requested.

No extension of time is believed to be necessary for the filing of this Amendment, but if an extension of time is required, applicants request that this be considered a petition therefor. The Commissioner is hereby authorized to charge any fees which may be required for such an extension to Deposit Account No. 11-1158.

Respectfully submitted,

Date: 9/7/00

Maurice M. Klee, Ph.D.
Reg. No. 30,399
Attorney for Applicant
1951 Burr Street
Fairfield, CT 06430
(203) 255-1400